Browse by author
Lookup NU author(s): Dr Ken BakerORCiD, Dr Dennis LendremORCiD, Dr Ben Thompson, Dr Arthur PrattORCiD, Professor John IsaacsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background Remission is now a realistic and achievable target for many patients with rheumatoid arthritis (RA) using disease-modifying anti-rheumatic drugs (DMARDs) prescribed in modern treat-to-target regimens. However, DMARDs carry risks of potentially serious adverse effects, and require regular and expensive blood monitoring. Recent studies suggest that half of patients with RA in remission can discontinue DMARDs without a flare of arthritis activity, though this cannot currently be reliably predicted.Objectives To identify baseline biomarkers that can predict sustained drug-free remission (DFR) versus arthritis flare following DMARD cessation.Methods Patients with established RA satisfying clinical (disease activity in 28 joints with CRP [DAS28-CRP]<2.4) and ultrasound (absence of power Doppler synovitis on a blinded 7-joint scan) remission criteria discontinued conventional synthetic DMARDs (methotrexate, sulfasalazine, and/or hydroxychloroquine) and were monitored for 6 months. The primary outcome was time-to-flare, defined as DAS28-CRP≥2.4. Baseline clinical and ultrasound parameters (synovial/tenosynovial greyscale and joint erosions), circulating levels of 26 cytokines/chemokines, and gene expression by peripheral CD4 +T cells (RNA sequencing) were assessed for their ability to predict time-to-flare and flare/DFR status by multivariate Cox regression and receiver-operating characteristic (ROC) analysis.Results 44 patients were eligible for DMARD cessation (table 1); 23 (52%) experienced an arthritis flare at a median (IQR) of 48 (31.5–86.5) days. A composite score incorporating five variables (three genes [currently subject to patent application], one cytokine [IL-27], and one clinical [ACR/EULAR Boolean remission]) differentiated future flare and DFR with an area under the ROC curve of 0.96 (95% CI: 0.92 to 1.00), sensitivity 0.91 (0.78–1.00) and specificity 0.95 (0.84–1.00) (figure 1).Conclusions Our study provides proof-of-concept evidence for the existence of biomarkers of DFR in RA. If validated in an external cohort, these biomarkers may hold promise in guiding DMARD withdrawal, with consequent minimisation of medication adverse events and healthcare costs.Acknowledgements KB was supported by the Wellcome Trust [102595/Z/13/A] and the NIHR Newcastle Biomedical Research Centre [BH136167/PD0045]. A patent application is currently in process regarding the gene expression biomarkers, the identify of which will subsequently be disclosed.Disclosure of Interest None declared
Author(s): Baker KF, Skelton AJ, Lendrem DW, Thompson B, Pratt AG, Isaacs JD
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: Annual European Congress of Rheumatology (EULAR 2018)
Year of Conference: 2018
Pages: 73
Online publication date: 12/06/2018
Acceptance date: 29/03/2018
ISSN: 0003-4967
Publisher: BMJ Publishing Group
URL: https://doi.org/10.1136/annrheumdis-2018-eular.2775
DOI: 10.1136/annrheumdis-2018-eular.2775
Series Title: Annals of the Rheumatic Diseases
